IN THE CLAIMS

Please amend the claims as follows:

Claims 1-9 (Canceled).

Claim 10 (Currently Amended): A method for treating a amyotrophic lateral sclerosis, which comprises administering a cyclohexenone long-chain alcohol compound, pharmaceutically acceptable salt, solvate or hydrate thereof, represented by the following formula (1):

$$\begin{array}{c}
R^1 \\
R^2 \\
X - OH \\
R^3
\end{array}$$
(1)

wherein each of R^1 , R^2 , and R^3 is a hydrogen atom or a methyl group; and X is a C10-C28 C15-C28 linear or branched alkylene group or a C10-C28 C15-C28 linear or branched alkenylene group to a patient in need thereof.

Claim 11 (Currently Amended): A method for treating at least one disorder amyotrophic lateral sclerosis caused by mutation in a superoxide dismutase gene, which comprises administering a cyclohexenone long-chain alcohol compound, pharmaceutically acceptable salt, solvate or hydrate thereof, represented by the following formula (1):

$$R^1$$
 R^2
 X
 R^3
 R^3

wherein each of R^1 , R^2 , and R^3 is a hydrogen atom or a methyl group; and X is a C10-C28 C15-C28 linear or branched alkylene group or a C10-C28 C15-C28 linear or branched alkenylene group to a patient in need thereof.

Claim 12 (Currently Amended): The method of claim 10, wherein the side elaim chain of the branched alkylene or alkenylene group of X is a C1-C10 alkyl group.

Claim 13 (Previously Presented): The method of claim 12, wherein the alkyl group is a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a tert-pentyl group, a hexyl group, an isohexyl group, a heptyl group, an octyl group, a nonyl group, or a decyl group.

Claim 14 (Previously Presented): The method of claim 12, wherein the alkyl group is a decyl group.

Claim 15 (Previously Presented): The method of claim 10, wherein at least one of R^1 , R^2 , and R^3 is a methyl group.

Claim 16 (Currently Amended): The method of claim 10, wherein X is a linear Previously Presented group.

Claim 17 (Currently Amended): The method of claim 10, wherein X is a linear C10-C18 group.

Claim 18 (Currently Amended): The method of claim 11, wherein the side elaim chain of the branched alkylene or alkenylene group of X is a C1-C10 alkyl group.

Claim 19 (Previously Presented): The method of claim 18, wherein the alkyl group is a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a tert-pentyl group, a hexyl group, an isohexyl group, a heptyl group, an octyl group, a nonyl group, or a decyl group.

Claim 20 (Previously Presented): The method of claim 18, wherein the alkyl group is a decyl group.

Claim 21 (Previously Presented): The method of claim 11, wherein at least one of R^1 , R^2 , and R^3 is a methyl group.

Claim 22 (Currently Amended): The method of claim 11, wherein X is a linear C10-C28-C15-C28 group.

Claim 23 (Currently Amended): The method of claim 11, wherein X is a linear C10-C18-C15-C18 group.

Claim 24 (Previously Presented): The method of claim 10, wherein the administering is orally, by injection or by suppository.

Application No. 09/890,969 Reply to Office Action of February 24, 2005.

Claim 25 (Previously Presented): The method of claim 11, wherein the administering is orally, by injection or by suppository.

Claim 26 (Previously Presented): The method of claim 10, wherein the daily dose for a human adult is 0.01-1000 mg.

Claim 27 (Previously Presented): The method of claim 11, wherein the daily dose for a human adult is 0.01-1000 mg.

Claim 28 (Previously Presented): The method of claim 10, wherein the daily dose for a human adult is 0.1-100 mg.

Claim 29 (Previously Presented): The method of claim 11, wherein the daily dose for a human adult is 0.1-100 mg.